Candidiasis market is estimated to be valued at USD 1,307.2 Mn in 2026 and is expected to reach USD 1,790.7 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.
The growth of the candidiasis market is supported by increasing prevalence of fungal infections, increase in rates of diabetes and HIV/AIDS infection, increase in use of broad-spectrum antibiotics and rise in awareness about early diagnosis & treatment. The growth of the market is driven by increasing awareness about antifungal therapies, emerging technologies for diagnostics and rising healthcare expenditure. However, global burden of antifungal resistant Candida species, recurrence after treatment and high costs of newer therapy are significant hurdles. Meanwhile, opportunities are emerging by developing new antifungal agents, improved access to generic medicines and increased investment in rapid diagnostics.
Based on Drug Class, Azoles segment is anticipated to capture more than 42.7% of the market as compared to others in 2026. Its broad-spectrum antifungal activity, low cost, ease of oral formulations delivery and use as the first-line treatment for superficial and systemic candidiasis infections give it leadership in this segment.
On the basis of Type, Vaginal Candidiasis is expected to hold a share of around 36.0% in the year 2026. This segment’s growth is propelled by its high prevalence across the globe, frequent recurrence in females, easy accessibility of over-the-counter antifungal drugs along with growing consciousness related to women health and early intervention.
Based on Route of Administration, the Oral segment is anticipated to account for a large market share in 2026, approximately 50.0%, due to simplicity of administration, convenience for patients and low-grade resources availability with price levels manageable by healthcare systems followed by a wide availability of oral antifungal therapies available both prophylactically and therapeutically.
On the basis of Distribution Channel, the Hospital Pharmacies segment is anticipated to control a share of about 45.0% in 2026 as extensive cases of severe and invasive candidiasis need expert antifungal treatments and institutional care.
By region, North America is estimated to lead the candidiasis market throughout 2026 with an approximate of 41.0% market share due to the presence of a developed healthcare infrastructure coupled with high cases of fungal infections among immunocompromised patients, and supportive reimbursement policies as well as a long track record of antifungal therapy innovations in this region. Asia Pacific is expected to be the fastest-growing region due to increasing incidence rates of fungal infections, improving healthcare infrastructure, low-cost availability of generic antifungal drugs, rising awareness regarding diagnosis and treatment along with increasing investment in healthcare systems by countries like China and India.
Prominent Players in the Candidiasis Market
-
Basilea Pharmaceutica Ltd.
Company Overview
- Headquarters: Allschwil, Switzerland
- Establishment Year: 2000
- Employee Strength: Approximately 150 employees
- Leadership: Mr. David Veitch, Chief Executive Officer
- Core Services/Products: Antifungal therapeutics, antibacterial medicines, oncology drug development, infectious disease treatments, and pharmaceutical research. Key antifungal products include Cresemba (isavuconazole).
SWOT Analysis
- Strengths
- Extensive experience in antifungal and anti-infective drug development.
- Cresemba for invasive fungal infections; commercial presence established.
- Weaknesses
- Different product pipeline as compared to big pharmaceutical industries.
- A very high dependency on revenues from partners and licensing.
- Opportunities
- Increased need for new antifungal treatments against resistant strains of Candida
- Expanding into emerging channels through partnerships.
- Threats
- Competition from generic antifungal products
- Reduction in regulatory criteria for marketing authorization of new therapies
-
Astellas Pharma Inc.
Company Overview
- Headquarters: Tokyo, Japan
- Establishment Year: 2005
- Employee Strength: Approximately 14,500 employees
- Leadership: Mr. Naoki Okamura, President & Chief Executive Officer
- Core Services/Products: Prescription pharmaceuticals, anti-infective therapies, oncology medicines, transplantation therapies, immunology treatments, and antifungal drugs including Mycamine (micafungin).
SWOT Analysis
- Strengths
- A large global pharmaceuticals business with established antifungal products.
- Robust research and development capabilities.
- Weaknesses
- The growth revenues are dependent on patented products.
- High R&D investment requirements.
- Opportunities
- Incidence of invasive fungal infections is increasing globally.
- Expansion of next-generation anti-infective therapies.
- Threats
- Patent expirations
- Pricing and reimbursement pressures in key markets
-
Grupo Ferrer Internacional, S.A.
Company Overview
- Headquarters: Barcelona, Spain
- Establishment Year: 1959
- Employee Strength: Approximately 1,800 employees
- Leadership: Mr. Mario Rovirosa, Chief Executive Officer
- Core Services/Products: Prescription pharmaceuticals, hospital specialty medicines, dermatology products, anti-infective therapies, and healthcare solutions.
SWOT Analysis
- Strengths
- Presence in specialty and hospital pharmaceutical industries.
- Established international distribution network.
- Weaknesses
- Reduced global footprint compared to those large multinational pharmaceutical companies.
- Restricted experience on more biologic therapies.
- Opportunities
- Broader antifungal & infectious disease treatment pipeline.
- Growth in emerging healthcare markets.
- Threats
- Intensified competition from generic makers.
- Regulatory changes in pharmaceutical commercialization.
-
Pacgen Life Science Corporation
Company Overview
- Headquarters: Vancouver, British Columbia, Canada
- Establishment Year: 2004
- Employee Strength: Approximately 50 employees
- Leadership: Mr. Michael Riedlinger, Chief Executive Officer
- Core Services/Products: Antimicrobial peptide therapeutics, anti-infective drug research, biotechnology development, and novel treatments for fungal and bacterial infections.
SWOT Analysis
- Strengths
- Innovative antimicrobial peptide technology platform.
- Focus on addressing antimicrobial resistance.
- Weaknesses
- Limited commercial product portfolio.
- Relying on favourable clinical development and funding results.
- Opportunities
- New antifungal therapies in demand
- Strategic partnerships with pharmaceutical companies.
- Threats
- Clinical development and regulatory risks.
- Existing antifungal manufacturers competing desperately
-
NovaDigm Therapeutics, Inc.
Company Overview
- Headquarters: Grand Forks, North Dakota, U.S.
- Establishment Year: 2005
- Employee Strength: Approximately 25 employees
- Core Services/Products: Immunotherapeutics, fungal and bacterial vaccines, Candida-targeted vaccine development, and infectious disease biotechnology research.
SWOT Analysis
- Strengths
- International experience in fungal immunotherapy and vaccine development;
- Differentiated pipeline against fungal infections
- Weaknesses
- Limited commercial-stage products.
- The dependence on endpoints in clinical trials and external funding.
- Opportunities
- Increasing prophylactics for recurrent candidiasis.
- Potential for any licensing or strategic partnerships.
- Threats
- Lengthy regulatory approval timelines.
- Competition from existing as well as new domain antifungal drug developers.
